1.
Alda JA, Soutullo C, Ramos-Quiroga JA, Quintero J, Hervás A, Hernández-Otero I, et al. Expert Recommendation: contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD). Actas Esp Psiquiatr [Internet]. 2014 Dec. 1 [cited 2024 Jul. 21];42(Suppl. 1):1-16. Available from: https://actaspsiquiatria.es/index.php/actas/article/view/1368